IL8 and Cathepsin B as Melanoma Serum Biomarkers

Melanoma accounts for only a small portion of skin cancer but it is associated with high mortality. Melanoma serum biomarkers that may aid early diagnosis or guide therapy are needed clinically. However, studies of serum biomarkers have often been hampered by the serum interference that causes false...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hongtao, Fu, Ting, McGettigan, Suzanne, Kumar, Suresh, Liu, Shujing, Speicher, David, Schuchter, Lynn, Xu, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111615/
https://www.ncbi.nlm.nih.gov/pubmed/21673904
http://dx.doi.org/10.3390/ijms12031505
Descripción
Sumario:Melanoma accounts for only a small portion of skin cancer but it is associated with high mortality. Melanoma serum biomarkers that may aid early diagnosis or guide therapy are needed clinically. However, studies of serum biomarkers have often been hampered by the serum interference that causes false readouts in immunological tests. Here we show that, after using a special buffer to eliminate the serum interference, IL-8 and cathepsin B levels were significantly elevated in melanoma patients (p < 0.05). More importantly, the combination of IL-8 and cathepsin B were also studied as a prognosis marker for melanoma mortality. Our study provides a novel approach to examine serum biomarkers.

Ejemplares similares